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Abstract
Background: Enterovirus 71 (EV71) is the main causative agent of Hand, Foot and Mouth disease (HFMD) and is associated
with severe neurologic complications and mortalities. At present, there is no vaccine or therapeutic available for treatment.
Methodology/Principal Finding: In this study, we generated two mAbs, denoted as mAb 51 and 53, both targeting the
same linear epitope on VP1 capsid protein, spanning amino acids 215–219. In comparison, mAb 51 belonging to isotype
IgM possesses neutralizing activity in vitro, whereas, mAb 53 belonging to isotype IgG1 does not have any neutralizing
ability, even towards its homologous strain. When mAb 51 at 10 mg/g of body weight was administered to the 2-week-old
AG129 mice one day prior to lethal challenge, 100% in vivo passive protection was observed. In contrast, the isotype control
group mice, injected with an irrelevant IgM antibody before the challenge, developed limb paralysis as early as day 6 post-
infection. Histological examination demonstrated that mAb 51 was able to protect against pathologic changes such as
neuropil vacuolation and neuronal loss in the spinal cord, which were typical in unprotected EV-71 infected mice. BLAST
analyses of that epitope revealed that it was highly conserved among all EV71 strains, but not coxsachievirus 16 (CA16).
Conclusion: We have defined a linear epitope within the VP1 protein and demonstrated its neutralizing ability to be isotype
dependent. The neutralizing property and highly conserved sequence potentiated the application of mAb 51 and 53 for
protection against EV71 infection and diagnosis respectively.
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Introduction
Enterovirus 71 or EV71 (BrCr strain) was first isolated and
identified in the United States in 1969 [1] , and was not associated
with hand, foot mouth disease (HFMD) until 1973, when small
epidemics broke out in Japan and Sweden [2,3]. From then on,
successive waves of EV71 outbreaks have been reported globally,
in United Kingdom, Australia, Sweden, Bulgaria, Japan, China,
Hong Kong, Taiwan, Malaysia and Singapore [2,4,5,6,7,8,9,10].
Over the past decade, the Asia-Pacific region was considered the
most seriously affected area, with occurrence of both major and
small-scale outbreaks associated with mortalities and neurologic
complications such as aseptic meningitis, fatal encephalitis and
poliomyelitis-like paralysis [11]. In the 1998 outbreak in Taiwan,
EV71 infected thousands of children and resulted in 405 severe
cases of neurologic disease, and 78 deaths in children [10,12].
HFMD had also emerged in China since 2008, resulting in
approximately 3.4 million of accumulated cases with 1400
fatalities [13]. Thus, EV71 represented a pre-eminent neurotropic
virus ever since the almost complete eradication of poliomyelitis.
Typical of a member of the family Picornaviridae, EV71 is a small,
non-enveloped, positive-stranded RNA virus, comprising four
capsid proteins VP1, VP2, VP3 and VP4. These capsid proteins
form the icosahedral structure, with VP1–3 exposed on the virus
surface and VP4 arranged internally [14]. Among these capsid
proteins, VP1 is believed to be the major contributor in viral
pathogenesis, playing critical roles in the adsorption and uncoating
processes of virus infection [15]. In addition, VP1 protein also
contains important neutralization sites. Studies utilizing high-titer
human neutralizing antibodies from cord blood samples collected
in Sarawak in 1999 demonstrated that these neutralizing
antibodies were more reactive towards the N-terminal half of
VP1 protein [16]. In contrast, another study revealed linear
neutralizing epitopes on VP1 protein [17], making VP1 a good
candidate for subunit vaccine. EV71 can be divided into 3
genotypes namely A, B and C. Genotypes B and C can be further
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29751divided into subgenogroups denoted as B1–5 and C1–5 respec-
tively. These genotypes and subgenogroups are designated based
on their VP1 gene sequences [18].
Up till now, health authorities can only rely on public health
surveillance and quarantine to prevent and control the spread of
the virus in the case of an outbreak, as EV71-specific vaccines or
therapeutics are not yet routinely available. Intravenous immu-
noglobulin (IVIG) is produced by extracting and pooling together
human immunoglobulin [19]. It has been employed as a
therapeutic agent that can effectively abolish or modify a variety
of infectious and inflammatory diseases such as Japanese
encephalitis, West Nile virus encephalitis and coxsackievirus
infection [19,20,21]. This method has also been used prophylac-
tically and therapeutically against enterovirus infection in neonates
and immunocompromised adults [22,23]. For instance, IVIG is
used extensively in the management of EV71 outbreaks in
Taiwan, Western Australia and also in China [24]. However,
preparation of a concentrated, biologically active, and safe
immune globulin for human use involves a complex immuno-
chemical method [19]. There are also issues pertaining to risks in
transmission of other human pathogens. Therefore, monoclonal
antibodies (mAb) offer a better alternative treatment, and have
indeed attracted much attention from the pharmaceutical industry
recently. In view of this, we are interested in developing anti-EV71
monoclonal antibodies which possess neutralizing ability against
all EV71 genotypes, to facilitate the study of their potential
applications for preventation and infection treatment.
In this study, we generated two mAb (designated mAb 51 and
53) by immunization of inactivated whole virus of EV71 strain
NUH0083-B5. The mAbs were fully mapped, and found to target
the same linear epitope on VP1 capsid protein, spanning amino
acids 215–219. However, they belonged to different immunoglob-
ulin isotypes and also displayed different neutralizing ability
against EV71 infection. We demonstrated that mAb 51 (belonging
to isotype IgM) possessed neutralizing activity in vitro against all
EV71 genotypes, and also conferred 100% passive protection in
vivo against EV71 infection prophylactically. In contrast, mAb 53
(belonging to isotype IgG1) did not possess any neutralizing ability
both in vitro and in vivo.
Results
Identification of specific mouse mAb against EV71
EV71 strain NUH0083-B5 was propagated and concentrated
from virus-infected rhabdomyosarcoma (RD) cells, and subjected
to BEI inactivation before injection into BALB/c mice. The anti-
sera raised against EV71 were analyzed by IFA, to test for
immunoreactivity of the anti-sera with EV71 virus. Mice were
subsequently sacrificed for cell fusion to generate hybridomas
secreting EV71-specific mAbs. The positive clones secreting
EV71-specific mAbs were identified by IFA, and selected for
subcloning by limiting dilution. Imumunospecificities of mAb 51
and 53 were assayed against total viral proteins and recombinant
capsid proteins (VP1, VP2 and VP3) by Western blotting. In
Figure 1, both mAb 51 and 53 reacted in the same manner, with a
single band observed in lane 2 (concentrated C4 virus) at an
apparent molecular mass of ,32 kDa. Its size corresponded to the
VP1 capsid protein (32.7 kDa). A single band with an apparent
size of 58 kDa could also be observed in lane 3 which was loaded
with total bacterial cell lysate expressing GST-tagged VP1
recombinant protein. Its size corresponded to the size of GST-
tagged VP1 protein (58 kDa). These data indicated that mAb 51
and 53 were specific for VP1 protein, and did not cross-react with
other capsid or viral proteins. Being able to react with the VP1
protein under denaturing conditions implied that the mAbs
targeted linear epitopes.
Epitope mapping of mAb 51 and 53
C-terminal truncated VP1 proteins were expressed as GST-
fusion proteins by cloning the corresponding fragments into
pGEX-4T-1 as described earlier. Respective recombinant plas-
mids were transformed into E. coli cells, and induced for protein
expression. As depicted in Figure 2A, a total of eight C-terminal
truncated protein fragments were expressed. Fragments A (1–66),
B (1–132), C (1–163), D (1–177), E (1–208), F (1–222), G (1–240)
and H (1–260) were successfully expressed and detected with anti-
GST mAb as shown in Figure 2B. Western blots also showed that
mAb 51 and 53 were only reactive to protein fragments F, G and
Figure 1. Characterization of Mab 51 and 53 by western blot
hybridization. Lane 1: RD Rhabdomyosarcoma cells total cell lysate.
Lane 2: Concentrated C4 virus. Lane3: GST-tagged VP1 recombinant
protein (,61 kDa). Lane4: GST-tagged VP2 recombinant protein
(,56 kDa). Lane 5: GST-tagged VP3 recombinant protein (,50 kDa).
mAb 51 and 53 were applied on respective membrane to test for their
immunoreactivity.
doi:10.1371/journal.pone.0029751.g001
Figure 2. Initial epitope mapping of mAb 51 and 53 by Western
blot analysis. (A) C-terminal truncated fragments of VP1 protein (A–
H), with peptide-spanning regions depicted. (B) Expression of protein
fragments determined with mAb against GST protein. Western blot
results indicated interaction of both mAb 51 and 53 with fragment F–H,
implying the location of the epitope within amino acids 208–222.
doi:10.1371/journal.pone.0029751.g002
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acids 208–222 of VP1 protein.
The C-terminal truncated proteins were then expressed from
amino acids 1 to 220, and with additional two amino acids for
each of the consecutive fragments at the C-terminal. Figure 3A
shows the schematic presentation of the protein fragmentation. In
Figure 3B, mAb 51 and 53 specifically recognized only fragment
f(1–220), indicating that the last amino acid of the epitope was
either at amino acid position 219 or 220. Another set of N-
terminal truncated proteins expressed from amino acids 210 to
297, and with deletion of one amino acid for each of the
subsequent fragments at the N-terminal as depicted in Figure 3A
were expressed to identify the first amino acid of the epitope.
Figure 3C shows that mAb 51 and 53 recognized fragment aa-ee,
indicating that the first amino acid of the epitope should be at
amino acid position 214. With the Western blot assays, we
deduced that the epitope should span amino acids 214–219 or
214–220. Subsequently, we expressed four putative epitopes fused
with GST protein, i.e. GST-KQEK, GST-HKQEKD, GST-
HKQEK, and GST-KQEKD. Figure 3D shows that mAb 51 and
53 specifically recognized only GST-HKQEKD and GST-
KQEKD only, indicating that the epitope of mAb 51 and 53
should KQEKD, spanning amino acids 215 to 219 within the VP1
capsid protein.
The epitope KQEKD was subjected to protein-protein BLAST
analysis against all enterovirus sequences in the GenBank, and
three single amino acid mutations at the first amino acid of the
epitope were identified in EV71. Lysine (K) was mutated into
glutamine (Q), glutamic acid (E) and arginine (R). Two of such
mutated sequences were found for each of the mutation.
Mutations of K to Q and E occurred in the EV71 sequences
from China reported from 2008 to 2009, while mutations of K to
R were found in EV71 sequences from Korea (2008) and Japan
(2004). Another mutation at the second amino acid from
glutamine (Q) to histidine (H) were also identified. In order to
evaluate the interactions of our mAbs with these epitopes, we
expressed the mutated epitopes with the GST tag. Figure 4 clearly
illustrates that mAb 51 and 53 were not capable of recognizing the
mutated epitopes QQEKD and EQEKD. However, they could
recognize the other two mutated epitopes, i.e. RQEKD and
KHEKD.
Specificity of mAb 51 and 53 to EV71 subgenogroups but
not to coxsackievirus A16
The epitope of mAb 51 and 53 was found to be highly
conserved and specific for EV71 strains. According to the BLAST
results, the mAb can recognize all EV71 strains except the four
sequences with mutations from K to Q and E. In addition, the
Figure 3. Detailed epitope mapping of mAb 51 and 53 by Western blot analysis. (A) C-terminal truncated fragments of VP1 protein (a–f), N-
terminal truncated fragments of VP1 protein (aa–hh), and GST-(epitope) peptide spanning regions as depicted. Expression of protein fragments was
determined with mAb against GST protein. (B) Western blot results of C-terminal truncated proteins (a–f) indicated interaction of both mAb 51 and 53
with fragment f only, implying that the last amino acid of the epitope should be at amino acid 219 or 220. (C) Western blot results of N-terminal
truncated proteins (aa–hh) indicated that the first amino acid of the epitope should be amino acid 214. Thus, the putative epitope of mAb 51 and 53
should span amino acid 214 to either 219 or 220. (D) Western blot analysis of GST-putative epitope proteins (GST-KQEK, GST-HKQEKD, GST-HKQEK,
GST-KQEKD) and GST as negative control. Interaction with both GST-HKQEKD and GST-KQEKD indicated that the epitope of mAb 51 and 53 is KQEKD
(215–219).
doi:10.1371/journal.pone.0029751.g003
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coxsackievirus A16, another important causative agent of HFMD.
The cross- reactivity of mAb 51 and 53 was tested against 11
heterologous EV71 strains as well as coxsackievirus A16 by
Western blot assay and IFA.
Figure 5 shows the partial alignment of VP1 amino acid
sequences of all EV71 subgenogroups (A, B1–B5, C1–C5 and
CA16). Epitope KQEKD (highlighted in grey) was found to be
fully conserved among the 11 representative strains of different
EV71 subgenogroups. In contrast, the epitope was found to be
rather different in CA16. Figure 6 confirmed that mAb 51 and 53
were able to cross-react with 8 representative EV71 subge-
nogroups (A, B2, B4, B5, C1, C2, C4 and C5). A single band of
approximately 32 kDa which corresponds to VP1 protein was
observed. A slight variation of the VP1 protein size was also
observed among the different EV71 strains. In addition, Figure 7
further illustrates that mAb 51 and 53 were able to cross-react with
all the 11 representative EV71 strains which were used for the
alignment analysis by IFA. With these supporting data, we could
confirm that mAb 51 and 53 are capable of cross-reacting with all
EV71 subgenogroups.
In determining whether mAb 51 and 53 can distinguish
between EV71 and coxsackievirus A16 (CA16) infections, RD
cells were infected with CA16 and IFA was conducted with mAb
51 and 53 (Figure 8). In that IFA, another mAb 4B12 directed
against the 3D polymerase protein was included as a positive
control to determine the infection of RD cells by CA16. The mAb
was found to be able to cross- react with CA16 owing to their
common epitope (unpublished data). We only observed signal in
Figure 8A and 8D where infected cells were recognized by mAb
4B12. However, no signals were observed with mAb 51 and 53 as
demonstrated in Figure 8B, 8C, 8E and 8F. Hence, we concluded
that our mAb did not cross react with the representative strain of
CA16. The result also corresponded with the protein alignment
results in Figure 5, where a rather different epitope was found in
CA16. This indicated that mAb 51 and 53 can distinguish between
EV71 and CA16 infections.
In vitro neutralizing activity of mAb 51 but not mAb 53
In testing whether mAb 51 and 53 have neutralizing activities
against homologous and heterologous strains of EV71, superna-
tants of the hybridomas were tested by the in vitro microneutraliza-
tion assay. RD cells were infected with 200 tissue culture infective
dose (TCID50) of representative strains from all subgenogroups as
listed in Table 1. Complete protection from cytopathic effects
(CPE) could be observed in RD cells when mAb 51 was applied.
Ascites derived from mAb 51 provided a neutralizing titer of about
1024, while the hybridoma supernatant showed a titer of 32
against homologous and heterologous strains of EV71. However,
mAb 53 did not display any neutralizing activity even against its
homologous B5 strain. Despite sharing a common epitope, only
mAb 51 possessed neutralizing ability. In characterizing the
immunoglobulin isotype of mAbs, mAb 51 was found to be isotype
IgM, and mAb 53 to be isotype IgG1. The results suggested that
the immunoglobulin isotype may play a crucial role in the
neutralization ability of the mAb, in the context of epitope
KQEKD.
Passive protection against lethal EV71 strain in AG 129
mice
A novel mouse model of EV71 infection was used to test the in
vivo protective efficacy of the antibodies. In the mouse model, 2-
week-old immunodeficient AG129 mice were found to be
susceptible to the infection with the non mouse-adapted EV71
strain HFM 41 via intraperitoneally (i.p.) route of inoculation. The
Figure 4. Evaluation of interactions of mAb 51 and 53 with
mutated epitopes. Mutated epitopes (QQEKD, EQEKD, RQEKD and
KHEKD) were expressed as GST-fusion proteins. Expression of proteins
was determined with mAb against GST. mAb interacted with the
authentic epitope (KQEKD) and mutated epitopes (RQEKD and KHEKD).
They failed to recognize the mutated epitopes QQEKD and EQEKD.
doi:10.1371/journal.pone.0029751.g004
Figure 5. Partial alignment of heterologous EV71 strains from all representative subgenogroups and coxsackievirus 16 based on
the VP1 amino acid sequences. Alignment of the epitope KQEKD was highlighted in grey, with 100% homology with all representative EV71
subgenotypes. A different epitope was observed in CA16 at amino acid position 215–219 of VP1 protein.
doi:10.1371/journal.pone.0029751.g005
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tations such as limb paralysis prior to death (unpublished data).
In the experiment, 2-week-old AG129 mice were injected i.p.
with mAb 51 at 10 mg/g of body weight one day prior to lethal
challenge with 10
7 PFU of EV71 strain HFM 41. An isotype
control group was injected with an irrelevant mouse IgM antibody
(isotype control) before challenge. The control animals which
received an isotype antibody developed severe limb paralysis as
early as day 6 post-infection, while the mice pre-treated with
mAb51 did not display any of the disease manifestations and
remained healthy throughout the experiment. Our result thus
suggested that the anti-EV71 antibody mAb 51 was able to
achieve 100% protection against the lethal EV71 challenge at a
dose of 10 mg/g of body weight.
Histopathologic examination of spinal cords of mice
Histopathologic examination of mice from isotype control group
revealed neuropil vacuolation and neuronal loss without inflam-
mation in the anterior horn in the spinal cord (Figure 9A and 9C).
The presence of EV71 infiltration into the spinal cord could also
be detected by mAb 4B12 (Figure 10A and 10C) and mAb 53
(results not presented). In contrast, we did not observe such
pathologic changes in mice from the prophylactic group. The
intact spinal cord morphology (Figure 9B, 9D and 10B) suggested
that mAb 51 was capable of conferring in vivo passive protection
against EV71 infection.
EV71 detection by quantitative reverse transcription
polymerase chain reaction (qRT-PCR)
The concentrations of the viral RNA copies were found to be
greater than 1610
5 copies/ml in isotype control (IgM) treated
mice, whereas in the prophylactics group, we observed lower than
10 copies of viral RNA/ml (Figure 11).
Discussion
Frequent HFMD epidemics caused by EV71 infection have
created great public awareness and concerns over the past decade,
especially in the Asia-Pacific region. Despite tremendous research
efforts, there is still a lack of effective vaccine and treatment
strategies against EV71 infections. IVIG has been employed
extensively in regions such as Taiwan and China for the
management of EV71 infections during outbreaks [24]. However,
Figure 7. IFA of Vero cells infected with heterologous strains of EV71 with mAb 51 and 53. (A) mAb 51 and (B) mAb 53 cross-reacted with
all the 11 representative EV71 strains (depicted on the top-left corner of each image). Immunofluoresent signals observed in the infected Vero cells as
well as in apoptotic cells indicated cross-reactivity between EV71 subgenotypes. Uninfected Vero cells served as negative control.
doi:10.1371/journal.pone.0029751.g007
Figure 6. Cross reactivity of mAb 51 and 53 with concentrated
EV71 viruses. Concentrated EV71 strains of various subgenogroups
(A, B2, B4, B5, C1, C4, C5 and C2) were separated on SDS-PAGE. A single
band of approximately 32 kDa was detected in all the viruses of
different subgenogroups. mAb 51 and 53 were able to cross-react with
all the EV71 strains tested. A slight variation of VP1 protein size was also
observed among the different EV71 subgenotypes.
doi:10.1371/journal.pone.0029751.g006
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agents, and may suffer from inconsistency in batch preparations.
We were motivated to study and develop a mAb which can confer
similar protection against EV71 infection. The major advantage of
using mAb over IVIG is its potential availability in large quantities,
renewable and of constant quality. In our study, we immunized
mice with inactivated whole EV71, and derived with two mAbs,
i.e. mAb 51 and 53.
These mAb were mapped by recombinant peptides and found
to recognize a common epitope spanning amino acids 215 to 219
within the VP1 capsid protein. The identified epitope is located
within the SP70 synthetic peptide (spanning amino acid residues
208–222) which was previously reported to harbor a linear
neutralizing epitope within homologous and heterologous EV71
strains [17]. However, the exact epitope within the 14 amino acid
peptide was not reported. Prior to our studies, there has been
report of mAb (IgG) reactive towards to SP70 peptide. However,
they only illustrated in vitro neutralization, without further
evaluation on its exact epitope and in vivo neutralization [25].
Ascites derived from mAb 51 was capable of neutralizing all
representative EV71 strains up to the highest dilution of 1:1024 in
vitro, while mAb 53 did not show any neutralizing ability even
against its homologous strain (NUS0083-B5). Isotyping of these
mAb revealed that mAb 51 belonged to isotype IgM, while mAb53
belonged to IgG1. This suggested that immunoglobulin isotypes
may play a crucial role for this particular epitope in its protective
property against EV71 infection.In a recent study from Taiwan, it
was demonstrated that a mAb (isotype IgG2a) which was reactive
to VP1 peptide (spanning amino acid residues 211–220), only
carried a neutralization titer of 1:64 and exclusively against its
homologous strain at a high concentration of 1 mg/ml, relative to
the concentration ascite [26]. Thus, the difference in isotype has
once again demonstrated variation in the neutralization activity.
Another study in China has also reported on a mAb with
neutralizing activity up to a dilution of 1:64. However, the mAb
possessed a different epitope from mAb 51 and its isotype was not
mentioned [27].
IgM is the first antibody isotype produced by the humoral
immune response, and exists as a pentamer with ten antigen-
binding sites. Thus, IgM can simultaneously binds to multivalent
antigens, contributing to an overall high avidity which is an
combined synergistic strength of single bond affinities [28]. The
importance of IgM in the neutralization of influenza virus by steric
hindrance has been suggested long before [29]. Other mechanism
such as aggregation of virus may be responsible for reduction of
viral infectivity in vivo [30]. In addition, IgM antibodies specific
against West Nile virus and Nocardia brasiliensis were also shown to
play important roles in providing protection against infection
[31,32,33]. Experiments could be done to unveil the mechanistic
role of mAb 51 in neutralizing EV71 infection which can enhance
the understanding of the protective role of Ig M in a typical EV71
infection.
mAb 51 was able to prophylactically confer 100% in vivo passive
protection in mice against heterologous B4 strain. Histopathologic
examination of the mice challenged with EV71 displayed neuropil
vacuolation and neuronal loss at the anterior horn of the spinal
cord. EV71 virus could also be detected by mAb 53 and 4B12 by
immunohistochemistry. These pathologic changes and detection of
Table 1. Representative strains of EV71 subgenotypes.
Name Accesion number Subgenotypes
BrCr U22521 A
RG EV71-VP1(B1) AF135901 B1
7423/MS/87 ETU22522 B2
RG EV71-VP1(B3) AF376093 B3
HFM41 AF316321 B4
NUH0083 FJ461781 B5
Y90-3761 AB433864 C1
NUH0075 FJ172159 C2
RG EV71-VP1(C3) AY125973 C3
75-Yamagata AB177813 C4
3437/SIN/06 GU222654 C5
doi:10.1371/journal.pone.0029751.t001
Figure 8. IFA of RD cells infected with CA16 virus. (A–C) IFA images were presented in bright field. (D–F) IFA images presented in fluorescence.
(A&D) Immunofluoresence signals were observed with mAb against 3D polymerase of EV71. (B&E) No immunofluoresence signal observed with mAb
51. (C&F) No immunofluoresence signal observed with mAb 53. Absence of immunofluoresence signal with mAb 51 and 53 indicated no cross-
reactivity with CA16.
doi:10.1371/journal.pone.0029751.g008
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suggested that mAb 51 could possess protective effects against
EV71 infection. The neutralizing ability of mAb 51 is comparable
with the antiserum elicited by the SP70 peptide which exhibited
complete protection from CPE in vitro and 80% protection against
EV71 infection in vivo [17,34]. In the previous study, the IgG
response induced by SP70 is as high as that induced by inactivated
virus, suggesting that the neutralizing activity is attributed to IgG.
Nevertheless, there is also a possibility that the protective effect
may be due to the IgM present in the polyclonal antiserum. In a
recent study on the performance of detecting IgM antibodies
against EV71 for early diagnosis, it was reported that the detection
rate of IgM is 95–100% for infected individuals after a month from
onset and can still be detected even 40 days after the onset of
infection [35]. The antiserum raised against SP70 collected 7
weeks after the first immunization may contain significant EV71-
specific IgM levels which may confer protective effects against
EV71 infection. However, there may also be other neutralizing
epitopes within the SP70 peptide that contribute to the neutralizing
activity in the antiserum raised against SP70. Therefore, additional
experiments could be conducted to produce polyclonal antibodies
against SP70, and then separating the population of IgM and IgG
isotypes to separately evaluate their neutralizing ability.
Humanized mAb 51 might offer an alternative reagent for
prevention during the management of a sudden EV71 outbreak
before identification of another better candidate. This particular
epitope carries neutralizing ability in the form of IgM. However,
IgG is conventionally the preferred class for therapeutics
antibodies due to its longer half life in vivo [36]. Therefore, more
neutralizing mAbs, preferably IgG can also be discovered by
producing human mAbs using transgenic mice or phage display in
the near future.
BLAST analyses of the KQEKD epitope revealed that it is fully
conserved among all EV71 strains but not in CA16. This result
was supported by the Western blot and IFA data. This makes mAb
53 a promising candidate for the development of a rapid
diagnostic kit as it is only specific for EV71 infection but not
CA16. Comparatively, mAb 53 of IgG isotype is more suitable for
this application due to its stability and ease in purification.
In conclusion, we have successfully generated two mAbs, and
have defined the exact neutralizing epitope within the SP70
peptide. We have discovered that this linear neutralizing epitope is
only effective for EV71 protection in the form of IgM, and may
confer similar protection as the immune sera derived from SP70-
immunized mice. Humanization of mAb 51 has potential
application for prevention of EV71 infections. Given that it
possesses a highly conserved epitope among all EV71 strains, mAb
53 has the potential to be applied in the development of a rapid
EV71 diagnostic kit.
Materials and Methods
Viruses growth and purification
EV 71 strains and CA 16 strain (Accession No. U05876) are
listed in Table 1. Other Enterovirus strains (B3-AF376093, C3-
AY125973, C4- EU703813) were generated using the human
RNA polymerase I reverse genetics system [37]. These viruses
were propagated in RD cells in DMEM (Gibco, USA) supple-
Figure 9. Histopathology of spinal cord of EV71-infected AG129 mice and prophylactically mAb-protected mice. (A) Cross-section of
spinal cord from isotype control mice with arrow pointing to region with neuropil vacuolation and neuronal loss without inflammation in the anterior
horn (at original magnification of 1006). (C) Higher power view of Figure 9A at original magnification of 2006. (B) Cross-section of spinal cord from
prophylactically mAb-protected mice showing no significant pathology (at original magnification of 1006). (D) Higher power view of Figure 9B
showing no significant pathology (at original magnification of 4006).
doi:10.1371/journal.pone.0029751.g009
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tested on RD cells by an end point dilution assay to determine the
TCID50 [38] and inactivated by binary ethyleneimine (BEI) as
described by Bahnemann [39,40]. Virus was concentrated ten-fold
by ultracentrifugation.
Mice immunization, generation and screening of
EV71-specific hybridoma cell line
Three SPF BALB/c mice were immunized with inactivated
virus strain NUH0083-B5 in 0.1 ml of PBS, emulsified with
adjuvant (Seppic, France) at a 1:1 ratio. Mice were subjected to
two boosters at 14-days intervals. Mice were euthanized three days
after subjecting to a final booster intraperitoneally, and. spleen
cells were harvested and fused with SP2/0 myeloma cells as
described previously [41]. The hybridoma cells were cultured in
DMEM with 20% FBS containing HAT or HT for 10 days.
Hybridoma cells were subjected to screening by IFA, and posi-
tive clones secreting EV71-specific monoclonal antibodies were
subcloned and cultured. All animal experiments were carried out
in accordance with the guides for Animal Experiments of the
National Institute of Infectious Disease (NIID). Experiment
protocols were reviewed and approved by Institutional Animal
Care and Use Committee of the Temasek Life Sciences
Laboratory (Project Approval No. TLL-10-017 & TLL-11-014),
National University of Singapore, Singapore.
Antibody detection by indirect immunofluoresence assay
Vero African green monkey kidney cells were used for antibody
screening. Cells were seeded overnight onto 96-well microtiter plates
and infected with EV71. Upon observation of CPE after 48 h at
37uC, cells were fixed with 4% paraformaldehyde (pH 7.4) for
20 min and permeabilized with 0.1% Triton-X/PBS for 5 min.
Cells were blocked with 5% FBS/PBS for 30 min, washed and
incubated in hybridoma cell supernatant or primary antibody
solution for 1 h followed by incubation in FITC-coupled secondary
antibodies for 1 h in room temperature. Cells were washed in 0.1%
Tween/PBS for thrice for 5 min each in between steps. Results were
documented with an inverted microscope (Olympus) with Nikon
ACT-1 software. Theimmunoglobulin isotype was determinedusing
a mouse monoclonal antibody isotyping kit (Santa Cruz).
Western blot analysis
The total proteins of EV71 strains and recombinant proteins of
EV71 capsid proteins (VP1 and its fragments, VP2 and VP3) were
Figure 10. Immunohistochemistry of spinal cord of isotype control mice and prophylactically mAb-protected mice. (A) Cross section
of spinal cord from isotype control mice with positive staining from mAb against 3D polymerase in the virus infected cells. (C) Higher power view of
Figure 10A at original magnification of 4006. Arrow pointing to virus infected cells (B) Cross section of spinal cord from ly mAb-protected mice with
no significant pathology (at original magnification of 2006).
doi:10.1371/journal.pone.0029751.g010
Figure 11. Analysis of EV71 viral copies by real-time PCR. Each
column represents the mean of triplicate assay with standard deviation.
Spinal cord from isotype control mice in the 7 dpi and prophylactically
mAb-protected mice in 20 dpi.
doi:10.1371/journal.pone.0029751.g011
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antibodies. Proteins were resolved by SDS-PAGE and electro-
blotted onto nitrocellulose membranes (Bio-Rad). Membrane were
blocked in 5% blotting grade milk/PBS, and incubated in
hybridoma cell supernatant or primary antibody solution for
1 h, followed with incubation in horse-radish-peroxidase coupled
secondary antibody at 1:10,000 dilution (Dako Cytomation) for
another hour. The membranes were subjected to three washes for
5 min each in 0.1% Tween-20/PBS in between steps and
developed with Amershem ECL Plus Western blotting detection
reagents (GE Healthcare).
Construction of GST fusion proteins incorporating VP1
fragments for epitope mapping
For obtaining the template sequence for expression of VP1
capsid protein of the B5 (NUH0083) strain, RNA was extracted
directly from the supernatant of infected RD cells using RNeasy
Mini Kit (QIAGEN) according to standard protocols. RT-PCR
was performed to generate cDNA of the VP1 sequence using VP1-
specific reverse primer (VP1-Xhol-R) and AMV reverse transcrip-
tase (Roche applied science). Fragments of VP1 capsid proteins
were expressed for characterization of monoclonal antibodies.
PCR were carried out with the panel of primers in Table 2, using
VP1 cDNA as the template sequence. PCR products were
subsequently digested with Xhol I and BamHI restriction enzymes,
and cloned into prokaryotic expression vector pGEX-4T-1 (GE
Healthcare). The recombinant plasmids were subjected to
sequencing and transformed into Escherichia coli (E.coli) BL21 cells
for expression of gluthathione S-transferase (GST) fusion proteins.
Positive bacterial clones were induced with 0.5 mM of isopropyl-
b-D-thiogalactopyranoside (IPTG). Induced cells were pelleted
and resuspended in PBS buffer. Total cell lysates were subjected to
western blot analysis. For expression of the specific epitope of the
mAbs, the DNA sequences were incorporated within the sense
primer together with the reverse primer pGEX-Aat II-R, with
pGEX-4-T1 as the template.
Ascites production and IgM purification
Ascites fluid containing monoclonal antibodies was produced
according to Current Protocol in Immunology from SPF BALB/c
mice [42]. IgM from ascites fluid was purified using IgM
purification kit (Thermo Scientific, USA) based on manufacturing
protocol.
Neutralizing antibody assay
Neutralization activity of monoclonal antibodies and ascites
fluid samples were determined by in vitro microneutralization
assay in RD cells. Two-fold serial monoclonal antibody dilutions
(50 ml each) were mixed with equal volume of 200 TCID50 of
virus, and incubated at 37uC for 1 h. The antibody-virus mixtures
were then added to the wells of the microtiter plates containing
RD cells. The highest dilution of monoclonal antibody that
inhibited virus growth was considered as the neutralization
antibody titer and was determined after incubation at 37uC for
96 h. Ascites was heated at 56uC for 30 min to inactivate
complements before use. Each assay was performed independently
for three times.
Experimental design for passive protection
The animal experiments were conducted with two weeks old
AG129 mice. These mice were obtained from B&K Universal
(UK). They were housed and bred under specific pathogen-free
conditions in individual ventilated cage. The institutional (NUS)
guidelines for animal care and use were strictly followed (Project
Approval No. IACUC-070/10(A2)11). To test the efficacy of the
antibody, these mice were randomly divided into two groups of 10
mice each. Group 1 mice (prophylactic group) were injected i.p.
with the purified mAb 51 antibody (0.1 ml in 50% glycerol
dissolved in PBS) at a concentration of 10 mg/g of body weight
one day whereas group two mice (isotype control group) was given
an equal amount of purified mouse IgM as isotype control
(eBioscience, San Diego, CA, USA). These two groups of mice
were subjected to lethal challenge with 10
7 plaque forming units
(PFU) of EV71 strain HFM 41 (5865/SIN/00009) via the i.p.
route [0.4 ml in PBS], 24 h post-injection of the immunoglobu-
lins. Survival rates and clinical scores of the mice were monitored
daily. Total limb paralysis was used as criterion for early
euthanasia.
Table 2. Oligonucleotides primers used for construction of
recombinant plasmids.
Primers Sequence (59R39)
VP1-BamH-F1 59-CCGGGATCCGGAGACAGGGTGGCAGATGT
VP1-Xhol-A(1–66)-R 59-CCGCTCGAGTGTCTCAATCATACTCTCAT
VP1-Xhol-B(1–132)-R 59-CCGCTCGAGATCAAAGCGCATATAGGTGA
VP1-Xhol-C(1–163)-R 59-CCGCTCGAGTGGTTTAGGAGCACCAGGGG
VP1-Xhol-D(1–177)-R 59-CCGCTCGAGAGGGTTTGTGGCTGTCTGCC
VP1-Xhol-E(1–208)-R 59-CCGCTCGAGGTACCCGTCGTAAAACCACT
VP1-Xhol-F(1–222)-R 59-CCGCTCGAGATATTCAAGATCTTTCTCCTG
VP1-Xhol-G(1–240)-R 59-CCGCTCGAGAGACCCCACGGTCCGCACCG
VP1-Xhol-H(1–260)-R 59-CCGCTCGAGTGCCCTGACATGCTTCATTC
VP1-BamH-f2 59- CCGGGATCCCCTCTGTCCCACCGTCTACA
VP1-Xhol-a(1–210)-R 59- CCGCTCGAGCGTGGGGTACCCGTCGTAAAACC
VP1-Xhol-b(1–212)-R 59- CCGCTCGAGTCCAAACGTGGGGTACCCGTCG
VP1-Xhol-c(1–214)-R 59- CCGCTCGAGGTGTTCTCCAAACGTGGGG
VP1-Xhol-d(1–216)-R 59- CCGCTCGAGCTGTTTGTGTTCTCCAAACG
VP1-Xhol-e(1–218)-R 59- CCGCTCGAGTTTCTCCTGTTTGTGTTCTCC
VP1-Xhol-e(1–220)-R 59- CCGCTCGAGAAGATCTTTCTCCTGTTTGTG
VP1-BamH-aa
(210–297)-F
59- CCGGGATCCTTTGGAGAACACAAACAGGAG
VP1-BamH-bb
(211–297)-F
59-CCGGGATCCGGAGAACACAAACAGGAGAAAG
VP1-BamH-cc
(212–297)-F
59- CCGGGATCCGAACACAAACAGGAGAAAGATC
VP1-BamH-dd
(213–297)-F
59- CCGGGATCCCACAAACAGGAGAAAGATCTTG
VP1-BamH-ee
(214–297)-F
59-CCGGGATCCAAACAGGAGAAAGATCTTGAATATGG
VP1-BamH-ff
(215–297)-F
59- CCGGGATCCCAGGAGAAAGATCTTGAATATGG
VP1-BamH-gg
(216–297)-F
59- CCGGGATCCGAGAAAGATCTTGAATATGGAGCG
VP1-BamH-hh
(217–297)-F
59- CCGGGATCCAAAGATCTTGAATATGGAGCGTG
VP1-Xhol-R 59- CCGCTCGAGAAGGGTAGTAATAGCGGTAC
VP1-BamH(epitope)-F 59-CCGGGATCC(Epitope)TGACGATCTGCCTCGCG
pGEX-AatII-R 59- ACTGACGTCTAAGAAACCATTATTATC
UTRF-59 59- TCCTCCGGCCCCTGAATG
Bold and italic letters indicate the sequence of restriction enzymes.
doi:10.1371/journal.pone.0029751.t002
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reaction
Spinal cord tissues from isotype control IgM-treated mice and
prophylactically protected mice were homogenized for total RNA
extraction by TRIzol reagent (Invitrogen). Extracted RNA (1 mg)
was used for qRT-PCR using the QuantiFast SYBR Green RT-
PCR kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. 59 UTR specific primers, i.e UTRF-59 and UTR-
R-59 (Table 2), were used for amplification. The qRT-PCR
thermal cycling conditions were applied at an initial incubation at
50uC for 12 min (reverse transcription), 95uC for 6 min (initial
PCR activation step), followed by 40 cycles each of 95uC for 12 s
(denaturation), 60uC for 30 s (combined annealing and extension),
and 77uC for 15 s. Melting curve data were collected from 50–
95uC at a ramping rate of 1uC/5 s, before finally cooling at 40uC.
The reaction was carried out using a Rotor-Gene Q real time
PCR cycler (Qiagen). The relative expression values were
normalized to the expression value of the b-tubulin housekeeping
gene. Serial ten-fold dilutions of recombinant plasmid DNA
containing full-length EV71 genome were included to generate a
standard curve for quantitative analysis.
Histopathologic and immunochemical analysis
Samples of spinal cords were collected, fixed in formalin,
embedded in paraffin blocks cut at 5 mm thickness (Leica Autocut
microtome model 2255, Leica Microsystems, Wetzler, Germany),
and attached to glass slides coated with poly-L-lysine. Slides were
subjected to staining with hematoxylin and eosin (H&E). In
addition, immunohistochemistry (IHC) technique was used to
detect the presence of viral antigen using mAb 53 and 4B12. The
mAb 4B12 recognizes the 3D polymerase of EV71 virus
(unpublished data). Sides were de-paraffinized with Histo-clear
II (National Diagnostics, Georgia, USA), and rehydrated in
sequentially graduated ethanol baths. Slides were subjected to
treatment according to manufacturer’s instructions (DAKO
Animal research kit).
Computational and sequence analyses
The identified epitope was used as the query sequence and
subjected to BLAST analysis against all enterovirus entries in the
National Center of Biotechnology Information database by the
protein-protein BLAST search. Amino acid sequences were
aligned by DNASTAR MegAlign using the Clustal method.
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